SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Nolan John J.) srt2:(2015-2019)"

Sökning: WFRF:(Nolan John J.) > (2015-2019)

  • Resultat 1-4 av 4
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • 2019
  • Tidskriftsartikel (refereegranskat)
  •  
2.
  • Ashton, Susan, et al. (författare)
  • Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo
  • 2016
  • Ingår i: Science Translational Medicine. - : American Association for the Advancement of Science (AAAS). - 1946-6234 .- 1946-6242. ; 8:325
  • Tidskriftsartikel (refereegranskat)abstract
    • Efforts to apply nanotechnology in cancer have focused almost exclusively on the delivery of cytotoxic drugs to improve therapeutic index. There has been little consideration of molecularly targeted agents, in particular kinase inhibitors, which can also present considerable therapeutic index limitations. We describe the development of Accurin polymeric nanoparticles that encapsulate the clinical candidate AZD2811, an Aurora B kinase inhibitor, using an ion pairing approach. Accurins increase biodistribution to tumor sites and provide extended release of encapsulated drug payloads. AZD2811 nanoparticles containing pharmaceutically acceptable organic acids as ion pairing agents displayed continuous drug release for more than 1 week in vitro and a corresponding extended pharmacodynamic reduction of tumor phosphorylated histone H3 levels in vivo for up to 96 hours after a single administration. A specific AZD2811 nanoparticle formulation profile showed accumulation and retention in tumors with minimal impact on bone marrow pathology, and resulted in lower toxicity and increased efficacy in multiple tumor models at half the dose intensity of AZD1152, a water-soluble prodrug of AZD2811. These studies demonstrate that AZD2811 can be formulated in nanoparticles using ion pairing agents to give improved efficacy and tolerability in preclinical models with less frequent dosing. Accurins specifically, and nanotechnology in general, can increase the therapeutic index of molecularly targeted agents, including kinase inhibitors targeting cell cycle and oncogenic signal transduction pathways, which have to date proved toxic in humans.
  •  
3.
  • Aaberge, Rolf, et al. (författare)
  • Tony Atkinson and his Legacy
  • 2017
  • Ingår i: The Review of Income and Wealth. - : Wiley. - 0034-6586 .- 1475-4991. ; 63:3, s. 411-444
  • Tidskriftsartikel (refereegranskat)abstract
    • Tony Atkinson is universally celebrated for his outstanding contributions to the measurement and analysis of inequality, but he never saw the study of inequality as a separate branch of economics. He was an economist in the classical sense, rejecting any sub-field labelling of his interests and expertise, and he made contributions right across economics. His death on 1 January 2017 deprived the world of both an intellectual giant and a deeply committed public servant in the broadest sense of the term. This collective tribute highlights the range, depth and importance of Tony's enormous legacy, the product of almost fifty years’ work.
  •  
4.
  • Suvitaival, Tommi, et al. (författare)
  • Lipidome as a predictive tool in progression to type 2 diabetes in Finnish men
  • 2018
  • Ingår i: Metabolism. - : Saunders Elsevier. - 0026-0495 .- 1532-8600. ; 78:January, s. 1-12
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: There is a need for early markers to track and predict the development of type 2 diabetes mellitus (T2DM) from the state of normal glucose tolerance through prediabetes. In this study we tested whether the plasma molecular lipidome has biomarker potential to predicting the onset of T2DM.METHODS: We applied global lipidomic profiling on plasma samples from well-phenotyped men (107 cases, 216 controls) participating in the longitudinal METSIM study at baseline and at five-year follow-up. To validate the lipid markers, an additional study with a representative sample of adult male population (n = 631) was also conducted. A total of 277 plasma lipids were analyzed using the lipidomics platform based on ultra-performance liquid chromatography coupled to time-of-flight mass spectrometry. Lipids with the highest predictive power for the development of T2DM were computationally selected, validated and compared to standard risk models without lipids.RESULTS: A persistent lipid signature with higher levels of triacylglycerols and diacyl-phospholipids as well as lower levels of alkylacyl phosphatidylcholines was observed in progressors to T2DM. Lysophosphatidylcholine acyl C18:2 (LysoPC(18:2)), phosphatidylcholines PC(32:1), PC(34:2e) and PC(36:1), and triacylglycerol TG(17:1/18:1/18:2) were selected to the full model that included metabolic risk factors and FINDRISC variables. When further adjusting for BMI and age, these lipids had respective odds ratios of 0.32, 2.4, 0.50, 2.2 and 0.31 (all p < 0.05) for progression to T2DM. The independently-validated predictive power improved in all pairwise comparisons between the lipid model and the respective standard risk model without the lipids (integrated discrimination improvement IDI > 0; p < 0.05). Notably, the lipid models remained predictive of the development of T2DM in the fasting plasma glucose-matched subset of the validation study.CONCLUSION: This study indicates that a lipid signature characteristic of T2DM is present years before the diagnosis and improves prediction of progression to T2DM. Molecular lipid biomarkers were shown to have predictive power also in a high-risk group, where standard risk factors are not helpful at distinguishing progressors from non-progressors.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-4 av 4
Typ av publikation
tidskriftsartikel (4)
Typ av innehåll
refereegranskat (4)
Författare/redaktör
Aaberge, Rolf (1)
Jäntti, Markus (1)
Bourguignon, Françoi ... (1)
Brandolini, Andrea (1)
Ferreira, Francisco ... (1)
Gornick, Janet G. (1)
visa fler...
Hills, John (1)
Jenkins, Stephen P. (1)
Marlier, Eric (1)
Micklewright, John (1)
Nolan, Brian (1)
Piketty, Thomas (1)
Radermacher, Walter ... (1)
Smeeding, Timothy M. (1)
Stern, Nicholas H. (1)
Stiglitz, Joseph (1)
Sutherland, Holly (1)
Kelly, Daniel (1)
Bengtsson-Palme, Joh ... (1)
Nilsson, Henrik (1)
Kelly, Ryan (1)
Li, Ying (1)
Moore, Matthew D. (1)
Liu, Fang (1)
Zhang, Yao (1)
Jin, Yi (1)
Raza, Ali (1)
Rafiq, Muhammad (1)
Zhang, Kai (1)
Khatlani, T (1)
Kahan, Thomas (1)
Sörelius, Karl, 1981 ... (1)
Batra, Jyotsna (1)
Roobol, Monique J (1)
Backman, Lars (1)
Yan, Hong (1)
Schmidt, Axel (1)
Lorkowski, Stefan (1)
Thrift, Amanda G. (1)
Zhang, Wei (1)
Hammerschmidt, Sven (1)
Patil, Chandrashekha ... (1)
Wang, Jun (1)
Pollesello, Piero (1)
Conesa, Ana (1)
El-Esawi, Mohamed A. (1)
Zhang, Weijia (1)
Kuusisto, Johanna (1)
Li, Jian (1)
Marinello, Francesco (1)
visa färre...
Lärosäte
Uppsala universitet (2)
Stockholms universitet (2)
Göteborgs universitet (1)
Högskolan i Halmstad (1)
Örebro universitet (1)
Lunds universitet (1)
visa fler...
Chalmers tekniska högskola (1)
Karolinska Institutet (1)
visa färre...
Språk
Engelska (4)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (3)
Naturvetenskap (1)
Samhällsvetenskap (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy